Recent Company News

• 06:07 AM ET Oct 05, 2026
  

  Vaxcyte reports topline data from OPUS-1 pivotal adult Phase 3 trial of VAX-31 pneumococcal conjugate vaccine candidate ($56.48, 0.00)

• 05:02 PM ET Oct 04, 2026
  

  Vaxcyte to present topline data from the OPUS-1 adult pivotal Phase 3 trial in conference call tomorrow (5-Oct) at 08:00ET ($56.48, 0.00)

• 06:33 AM ET Sep 28, 2026
  

  Kodiak Sciences reports phase 3 DAYBREAK study meets primary endpoint ($32.35, 0.00)

• 09:39 PM ET Sep 22, 2026
  

  NICE recommends AbbVie's Imbruvica with R-CHOP for untreated mantle cell lymphoma when ASCT is suitable

• 04:21 AM ET Aug 25, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (68 total)

• 05:02 PM ET Jul 22, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 02:56 PM ET Jul 22, 2026
  

  Transcript Intelligence: Lonza Group Q2 Earnings Guidance

• 02:55 PM ET Jul 22, 2026
  

  Transcript Intelligence: Lonza Group Q2 Earnings Themes

• 02:55 PM ET Jul 22, 2026
  

  Transcript Intelligence: Lonza Group Q2 Earnings Q&A

• 08:48 AM ET Jul 22, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market